Ankyra Therapeutics is a clinical-stage biotech developing anchored-drug conjugates to trigger long lasting anti-tumor response without compromising safety.

Ankyra Therapeutics

Ankyra Therapeutics | 1,812 followers on LinkedIn. Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response | Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Co-founder/Managing Partner, Borealis Ventures

Phil Ferneau

Experienced Quality Assurance professional

Dayna Resi

Lynn Nicole (Dickerson)

Chief Process and Manufacturing Officer at Ankyra Therapeutics

Greg Zarbis-Papastoitsis

Ankyra Therapeutics announces the first visceral tumor patient dosed #anchoredimmunotherapy #anchoreddrugconjugates https://shorturl.at/nclWG

Ankyra Therapeutics is excited to announce the appointment of Julia G. Butchko, Ph.D. and Tara Withington, CAE to the Ankyra Board of Directors. https://shorturl.at/UHkXq

Ankyra Therapeutics President and CEO Howard Kaufman will be speaking at today's SITC Summit on Intralesional Immunotherapy #SITC #Anchoredimmunotherapy #immunotherapy

Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn

Ankyra Therapeutics President and CEO will be the featured speaker at Drug Discovery News upcoming webinar about Combination therapy for Cancer on April 18, 2024 at 1pm ET https://lnkd.in/exKhS5NZ

Ankyra Therapeutics has announced an exclusive licensing agreement for JEN-001 with Jenga Biosciences. https://lnkd.in/eXsQxYd2

Ankyra Therapeutics is excited to announce the first patient has been dosed in our Phase 1 clinical trial evaluating ANK-101, an Anchored Immune Medicine, for the treatment of solid tumors. Read more in the press release: https://rb.gy/n6vaw7

The Ankyra Therapeutics team proudly participated in the Life Science Cares Boston #Holidayhelpers program this holiday season.

This month, results from a preclinical study demonstrating potent anti-tumor activity of our lead program ANK-101 were published in the December issue of The Journal of Clinical Investigation Insight. Data from the study on ANK-101, a novel tumor-directed anchored immune medicine (AIM), demonstrated retention at the tumor site for approximately four weeks, overcoming the challenges of intratumoral injection. To read more and to view the paper, "Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment": https://lnkd.in/euwp_NEF

Metric
Company Name	Ankyra Therapeutics
Symbol
MSH ID	COM:ANKYRATX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	ankyratx.com
LinkedIn	ankyratx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ANKY

COM:ANKYRATX

Ankyra Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue